FDA Removes 12 Peptides from Category 2: What It Actually Means

What Just Happened

On April 15, 2026 — yesterday — the FDA announced that 12 peptide bulk drug substances will be removed from its Category 2 "significant safety risks" list, effective April 22, 2026. At the same time, the FDA scheduled formal Pharmacy Compounding Advisory Committee (PCAC) meetings to determine the long-term regulatory fate of these compounds.

This follows weeks of anticipation after HHS Secretary Robert F. Kennedy Jr. signaled on The Joe Rogan Experience (February 27, 2026) that the administration would act to restore access to peptides restricted during the Biden administration.

The 12 Peptides Leaving Category 2

The following compounds are exiting the restricted list:

PCAC Review — July 23, 2026:

BPC-157 (acetate and free base)
KPV (acetate and free base)
MOTs-c (acetate and free base)
TB-500 / Thymosin Beta-4 Fragment (acetate and free base)

PCAC Review — July 24, 2026:

Emideltide / DSIP (acetate and free base)
Epitalon (acetate and free base)
Semax (acetate and free base)

PCAC Review — By February 2027:

Cathelicidin (LL-37)
GHK-Cu (injectable routes)
Dihexa Acetate
Mechano Growth Factor, Pegylated (PEG-MGF)
Melanotan II

Note on GHK-Cu: This compound has an unusually complex status. Injectable GHK-Cu is being removed from Category 2, while non-injectable GHK-Cu is simultaneously being removed from Category 1 (the active evaluation list). Both forms are scheduled for unified PCAC review before February 2027.

Critical Distinction: Removal ≠ Authorization

This is the most important thing to understand, and it's being misreported in much of the press coverage.

Removing a compound from Category 2 does not mean:

It is legal to compound
It is on the 503A bulk drug substances list
Pharmacies can start preparing it immediately
It has been cleared for safety or efficacy

What it actually means:

The "significant safety risks" designation — which was the basis for FDA enforcement actions — is gone
The compound enters a regulatory gray zone until PCAC acts
PCAC will formally evaluate whether these compounds should be added to the 503A bulk drug substances list
The PCAC recommendation is advisory; the FDA can accept, modify, or reject it

A legal analysis from Orrick described this well: compounding pharmacies "should still exercise caution regarding these peptides until their status is determined by FDA."

Why Did This Happen?

Three factors converged:

1. Political pressure from RFK Jr. Secretary Kennedy publicly stated he believes the 2023 Category 2 designations were illegal. He argued the FDA can only designate Category 2 status if there are demonstrable safety concerns, and that these compounds lack such evidence. He described himself as a "big fan" of peptides and has personal experience using them for injury recovery.

2. The black market problem. Kennedy and others argued that the 2023 ban drove demand to unregulated gray-market sources — overseas vendors with no quality controls or lab testing. The position is that restoring a legal, regulated compounding pathway produces better safety outcomes than prohibition.

3. Nomination withdrawals. The immediate technical trigger was that the original nominators withdrew their nominations for these 12 compounds. Under the 503A process, this removal-by-withdrawal then obligates the FDA to schedule PCAC review for formal evaluation.

What Comes Next — The PCAC Process

The Pharmacy Compounding Advisory Committee is an FDA advisory body that evaluates whether specific bulk drug substances should be authorized for compounding. Here's how it works:

Written public comments are submitted to the docket (FDA-2025-N-6895) and provided to the committee. Deadline for the July meeting: July 9, 2026.
Oral presentations can be requested by stakeholders (deadline: June 30, 2026).
PCAC meets and issues a recommendation — typically "add to the bulks list," "do not add," or "needs more data."
FDA decides whether to accept the recommendation and formally adds the compound to the 503A bulk drug substances list (or not).

The PCAC recommendation is advisory, not binding. Given the current administration's posture, outcomes may differ from the Biden-era PCAC precedent, which voted against inclusion for similar withdrawn nominations.

Why This Matters for Patients and Clinicians

If you've been using these peptides through compounding pharmacies: Their legal status between April 22 and the PCAC decisions is genuinely ambiguous. The enforcement risk is reduced (no Category 2 designation), but full authorization hasn't been granted. Work with your prescribing physician and pharmacy's compliance team.

If you've been accessing these through gray-market sources: This regulatory trajectory strongly suggests a legitimate, prescription-based pathway is coming. The push toward compounding pharmacies is explicit — RFK Jr. specifically framed this as replacing unregulated imports with "ethical suppliers."

For clinics and telehealth providers: The July PCAC meeting is the first major milestone. If PCAC recommends adding BPC-157, TB-500, and the other July compounds to the 503A list, clinical adoption could accelerate very quickly in Q3 2026.

The Skeptical View

Not everyone is optimistic. Public Citizen's Health Research Group director Robert Steinbrook stated: "There is no credible reason to believe that peptides that were deemed unproven or unsafe in 2023 are miraculously safe and effective in 2026."

There are legitimate concerns that the current administration may stack the reconstituted PCAC with allies aligned with Kennedy's views — similar to what occurred at the CDC with vaccine advisory committees under this administration. If the committee is stacked, the "public scientific review" process could rubber-stamp political decisions rather than function as independent evaluation.

The regulatory landscape is genuinely fluid. Outcomes are not guaranteed.

The Bottom Line

The April 15 announcement is the most consequential peptide regulatory action since the 2023 Category 2 designations that sparked this whole controversy. For patients, clinicians, compounding pharmacies, and the broader wellness industry, it represents a meaningful step toward restoring legal access — but it is not the finish line.

Mark your calendars:

April 22, 2026 — Category 2 removal effective
July 9, 2026 — Public comment deadline for PCAC
July 23–24, 2026 — PCAC meeting for Group 1 (BPC-157, TB-500, Semax, Epitalon, MOTs-c, KPV, Emideltide)
By February 2027 — PCAC meeting for Group 2 (GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF)

We will update the FDA Tracker and this article as events develop.

Sources: Orrick Law Firm Analysis · RAPS · Ars Technica

This article is for educational and informational purposes only and does not constitute medical or legal advice.